Digestome Therapeutics announces that the first patient has been enrolled in a Phase 1 clinical trial investigating DGX-001

Digestome Therapeutics announces that the first patient has been enrolled in a Phase 1 clinical trial investigating DGX-001 - an oral, vagus nerve stimulating therapeutic targeting non-motor symptoms in patients with #Parkinsons

Digestome Therapeutics Announces First Patient Enrolled in Phase 1 Clinical Trial of DGX001

SAN FRANCISCO, March 8, 2022 – Digestome Therapeutics, a biotech company developing first-inclass therapeutics that stimulate the central nervous system (CNS) via the gut-brain-axis,

announced that the first patient has been enrolled in a Phase 1 clinical trial investigating DGX-001.

The trial will feature safety as the primary endpoint and will also investigate a variety of

biomarkers to assess the biological and clinical response to DGX-001.

DGX-001 is a first-in-class oral, vagus nerve stimulating therapeutic being initially developed for the

treatment of negative symptoms and cognitive impairment in patients with schizophrenia, and for

non-motor symptoms in patients with Parkinson’s Disease. The innovative drug is gut-acting and

gut-restricted. It acts on the CNS via the vagus nerve, thereby modulating parasympathetic activity

and inflammation in the body. DGX-001 has been developed based on the research done by Dr.

Kousaku Ohinata at Kyoto University to discover functional peptides from various food proteins.

“We are excited to bring DGX-001 forward into the clinic. This represents significant clinical

milestone for Digestome and our first-in-class gut-brain-axis therapeutic platform,” said Ken Horne,

President of Digestome Therapeutics. “This is an important first step towards helping negative

symptoms and cognitive impairment in schizophrenia patients, as well as non-motor symptoms in

Parkinson’s Disease patients. Over 60% of schizophrenia patients have clinically significant

negative symptoms, and over 70% of Parkinson’s patients have clinically significant non-motor

symptoms. There are no approved therapies for such schizophrenia patients and these patients’

symptoms go largely untreated. DGX-001’s unique pharmacology and mechanism of action are

particularly well suited for these indications,” continued Mr. Horne.

The trial is anticipated to be completed in the fourth quarter of 2022.

About Digestome Therapeutics:

digestometx.com

Contact:

[e-mail]

digestometx.com/wp-content/...